Baidu
map

Eur Heart J:房颤患者消融后短期口服胺碘酮喜忧参半

2014-09-10 cath 编译 医学论坛网

ESC2014公布的一项研究表明,阵发性或永久性心房颤动(简称房颤)患者消融后短期口服胺碘酮治疗未显著减少其房性快速性心律失常的复发,但在消退期,这种治疗方法可将房性心律失常相关住院率和心脏电复律减半甚至更少。论文9月2日在线发表于《欧洲心脏杂志》(Eur Heart J)。 接受导管消融治疗的房颤患者常在消融后数月内反复发生心律失常。该研究旨在探讨房颤射频消融后早期预防性短期应用胺碘酮是否可以

ESC2014公布的一项研究表明,阵发性或永久性心房颤动(简称房颤)患者消融后短期口服胺碘酮治疗未显著减少其房性快速性心律失常的复发,但在消退期,这种治疗方法可将房性心律失常相关住院率和心脏电复律减半甚至更少。论文9月2日在线发表于《欧洲心脏杂志》(Eur Heart J)。

接受导管消融治疗的房颤患者常在消融后数月内反复发生心律失常。该研究旨在探讨房颤射频消融后早期预防性短期应用胺碘酮是否可以减少晚期复发。

该研究名为AMIO-CAT,是一项两中心、随机、双盲、安慰剂对照研究。研究者们随机纳入了212例接受导管消融治疗的房颤患者,并根据房颤类型(阵发性/永久性)和既往房颤消融史对其进行分层,将其随机分为射频消融后进行为期8周的胺碘酮或安慰剂治疗。

结果随访了6个月。根据意向治疗原则进行分析显示,研究者们可获得206例患者的主要终点事件,即3个月的消退期受试者出现房性快速心律失常持续时间>30 s。胺碘酮组和安慰剂组这一发生率分别为39%(42/107)和48%(48/99)(P= 0.18)。

在次要终点方面,胺碘酮组的房性快速心律失常相关住院率[比值比(RR)= 0.43,P= 0.006]和心脏电复律(RR= 0.36,P= 0.0004)显著降低。

原始出处

Darkner S1, Chen X2, Hansen J3, Pehrson S2, Johannessen A3, Nielsen JB2, Svendsen JH4.Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).Eur Heart J. 2014 Sep 2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1297741, encodeId=cbfd129e741aa, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355919, encodeId=238013559196b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421604, encodeId=48e714216049b, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562263, encodeId=0200156226315, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614250, encodeId=7feb16142501a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1297741, encodeId=cbfd129e741aa, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355919, encodeId=238013559196b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421604, encodeId=48e714216049b, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562263, encodeId=0200156226315, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614250, encodeId=7feb16142501a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=)]
    2014-09-12 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1297741, encodeId=cbfd129e741aa, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355919, encodeId=238013559196b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421604, encodeId=48e714216049b, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562263, encodeId=0200156226315, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614250, encodeId=7feb16142501a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1297741, encodeId=cbfd129e741aa, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355919, encodeId=238013559196b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421604, encodeId=48e714216049b, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562263, encodeId=0200156226315, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614250, encodeId=7feb16142501a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=)]
    2014-09-12 爆笑小医
  5. [GetPortalCommentsPageByObjectIdResponse(id=1297741, encodeId=cbfd129e741aa, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355919, encodeId=238013559196b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421604, encodeId=48e714216049b, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562263, encodeId=0200156226315, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614250, encodeId=7feb16142501a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Sep 12 00:28:00 CST 2014, time=2014-09-12, status=1, ipAttribution=)]

相关资讯

OCC 2014:戚文航教授谈心衰患者中心律失常的治疗

东方心脏病学会议(OCC2014)上,上海瑞金医院戚文航教授介绍了心衰患者中心律失常的药物治疗方法。 上海瑞金医院戚文航教授 心律失常抑制与生存率、死亡率的矛盾关系 CAPS、CAST、CASTⅡ、IMPACT等临床研究显示,在缺血性心律失常治疗中,Ⅰ类抗心律失常药物可显著抑制心律失常,但死亡率显著增加,这种现象同样见于心力衰竭、心肌病的心律失常治疗中。心律失常与心力衰竭互为因果

专家解读2014AHA/ACC/HRS心房颤动患者管理指南

2014年3月,美国心脏协会(AHA)、美国心脏病学会(ACC)、美国心律学会(HRS)联合美国胸外科学会(STS)共同发布了《2014年心房颤动患者管理指南》。该指南基于2006年版AHA/ACC房颤管理指南,融入2011年发表的两次更新,并参考最新的临床研究证据、新的治疗策略和药物等而制定。其制定的宗旨正如指南前言中指出的:“指南旨在制定满足大多数情况下大多数患者需要的治疗方案,而最终决策

马长生:心房颤动的卒中、出血及风险评分CHA2DS2VASC

心房颤动(房颤)是临床上最常见的心律失常之一。同正常人群相比,房颤具有很高的致死率和致残率,血栓栓塞并发症是其致残、致死的主要原因。非瓣膜性房颤患者的卒中风险是正常人的 5~6倍,年发生率约为5%。因此,预防卒中对房颤患者尤为重要。口服抗凝药是目前预防房颤血栓栓塞并发症最有效的方法,调整剂量的华法林可使房颤卒中的相对危险降低68%,优于单用或双联抗血小板治疗。真实世界研究荟萃同时表明,华法林显

ISC 2014:植入式监测仪可发现不明原因卒中患者的心房颤动

2014国际卒中大会(ISC)上,Richard A. Bernstein博士(美国西北大学)报告的CRYSTAL-AF研究结果显示,对于发生不明原因卒中的患者,使用植入式心脏监测仪的心房颤动(房颤)检出率显著高于标准监测。研究者表示,房颤是卒中最重要的危险因素之一,可通过抗凝治疗预防,监测仪能显著降低卒中复发率。研究入选441例不明原因卒中患者,所有患者在卒中90天内接受至少24小时的标准心脏监

黄从新:心房颤动的当代认识和展望

心房颤动(房颤)是临床上最常见的快速性心律失常之一。据不完全统计,中国大陆大约有700万房颤患者,美国大约有200万房颤患者。房颤的发病率增长迅速,从1985至1999年,全美因房颤住院的患者几乎上升了3倍,我国部分地区1999 ~2001年间房颤占同期心血管住院病人比例呈逐年上升趋势,平均为7.9%。房颤可致栓塞、心力衰竭等不良后果,使患者生活质量降低、死亡率升高,此一直是心血管领域研究的热

陈诤&刘少稳:地高辛在心房颤动治疗中的误区

洋地黄类药物治疗心房颤动(房颤)历史悠久,目前国内许多医生仍将地高辛作为控制房颤患者心室率的一线用药。然而近年来国外的一些研究表明地高辛治疗房颤不但没有显著疗效,甚至增加死亡率,而国内相关研究和认识尚存在不足。因此,本文现就对地高辛在房颤治疗中的误区进行综述。 1. 洋地黄类药物治疗房颤的作用机制 房颤是临床上最常见的心律失常。心室率紊乱、心功能受损和心房附

Baidu
map
Baidu
map
Baidu
map